Market Therapeutics (MRKR +5.7%) surges to seven-month highs on heavy volume following yesterday’s announcement that updated clinical results from a Phase 1/2 trial with MultiTAA therapy in patients with pancreatic adenocarcinoma were selected for oral presentation during a plenary session at an upcoming American Association for Cancer Research conference.
MRKR is seeking to develop next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.